## Kevin J Clerkin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1605812/publications.pdf

Version: 2024-02-01

54 3,506 23 50 papers citations h-index g-index

54 54 54 6990 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	COVID-19 and Cardiovascular Disease. Circulation, 2020, 141, 1648-1655.	1.6	1,398
2	The Variety of Cardiovascular Presentations of COVID-19. Circulation, 2020, 141, 1930-1936.	1.6	465
3	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	1.8	206
4	Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1165.	3.0	170
5	Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 540-545.	0.3	107
6	Regional Differences in Recipient Waitlist TimeÂand Pre- and Post-Transplant Mortality After the 2006 United Network for OrganÂSharing Policy Changes in the Donor Heart Allocation Algorithm. JACC: Heart Failure, 2014, 2, 166-177.	1.9	77
7	Indications for and Findings on Transthoracic Echocardiography in COVID-19. Journal of the American Society of Echocardiography, 2020, 33, 1278-1284.	1.2	74
8	The Impact of Obesity on Patients BridgedÂto Transplantation With Continuous-Flow LeftÂVentricular AssistÂDevices. JACC: Heart Failure, 2016, 4, 761-768.	1.9	67
9	Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock. Journal of Heart and Lung Transplantation, 2018, 37, 1313-1321.	0.3	61
10	The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection. Journal of Heart and Lung Transplantation, 2016, 35, 1059-1066.	0.3	56
11	Impact of long term left ventricular assist device therapy on donor allocation in cardiac transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 188-195.	0.3	52
12	Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the <i>JAHA</i> Editors. Journal of the American Heart Association, 2020, 9, e017013.	1.6	52
13	Implantable Cardioverter-Defibrillators inÂPatients With a Continuous-Flow LeftÂVentricular Assist Device. JACC: Heart Failure, 2017, 5, 916-926.	1.9	47
14	The Prognostic Value of Electrocardiogram at Presentation to Emergency Department in Patients With COVID-19. Mayo Clinic Proceedings, 2020, 95, 2099-2109.	1.4	43
15	Constructing bioactive peptides with pH-dependent activities. Peptides, 2009, 30, 1523-1528.	1.2	41
16	Impact of Socioeconomic Status on Patients Supported With a Left Ventricular Assist Device. Circulation: Heart Failure, 2016, 9, .	1.6	37
17	Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 862-870.	0.3	36
18	Admission Cardiac Diagnostic Testing with Electrocardiography and Troponin Measurement Prognosticates Increased 30â€Day Mortality in COVIDâ€19. Journal of the American Heart Association, 2021, 10, e018476.	1.6	35

#	Article	IF	CITATIONS
19	Dobutamine stress echocardiography is inadequate to detect early cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2016, 35, 1040-1041.	0.3	31
20	The role of implantable cardioverter defibrillators in patients bridged to transplantation with a continuous-flow left ventricular assist device: A propensity score matched analysis. Journal of Heart and Lung Transplantation, 2017, 36, 633-639.	0.3	30
21	Prevalence of polyreactive innate clones among graft-Âinfiltrating B cells in human cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2018, 37, 385-393.	0.3	30
22	Predictors of survival and ability to wean from short-term mechanical circulatory support device following acute myocardial infarction complicated by cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 755-765.	0.4	26
23	Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays. Transplantation Direct, 2017, 3, e218.	0.8	25
24	Profiling non-HLA antibody responses in antibody-mediated rejection following heart transplantation. American Journal of Transplantation, 2020, 20, 2571-2580.	2.6	22
25	Understanding the Link Between Obesity and Severe COVID-19 Outcomes: Causal Mediation by Systemic Inflammatory Response. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e698-e707.	1.8	21
26	Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System. JACC: Heart Failure, 2022, 10, 12-23.	1.9	21
27	Outcomes of Multiple Listing for Adult Heart Transplantation in the United States. JACC: Heart Failure, 2015, 3, 933-941.	1.9	20
28	Recovery With Temporary Mechanical Circulatory Support While Waitlisted for Heart Transplantation. Journal of the American College of Cardiology, 2022, 79, 900-913.	1.2	20
29	Extracorporeal photopheresis and its role in heart transplant rejection: prophylaxis and treatment. Clinical Transplantation, 2021, 35, e14333.	0.8	19
30	New developments for the detection and treatment of cardiac vasculopathy. Current Opinion in Cardiology, 2017, 32, 316-325.	0.8	18
31	Mechanical Circulatory Support as a Bridge to Cardiac Retransplantation: A single center experience. Journal of Heart and Lung Transplantation, 2015, 34, 161-166.	0.3	17
32	Comparison of early versus delayed timing of left ventricular assist device implantation as a bridge-to-transplantation: An analysis of the UNOS dataset. International Journal of Cardiology, 2016, 203, 929-935.	0.8	15
33	Outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clinical Transplantation, 2020, 34, e14028.	0.8	15
34	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. New England Journal of Medicine, 2020, 382, 2354-2364.	13.9	15
35	Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system. Clinical Transplantation, 2020, 34, e14109.	0.8	14
36	Donorâ€derived cellâ€free DNA is associated with cardiac allograft vasculopathy. Clinical Transplantation, 2021, 35, e14206.	0.8	14

#	Article	IF	Citations
37	The cardiac intensive care unit and the cardiac intensivist during the COVID-19 surge in New York City. American Heart Journal, 2020, 227, 74-81.	1.2	13
38	Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?. Circulation: Heart Failure, 2021, 14, e007916.	1.6	13
39	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. Journal of Cardiac Failure, 2022, 28, 1149-1157.	0.7	12
40	Myocardial Injury in COVID-19 Patients. Journal of the American College of Cardiology, 2020, 76, 547-549.	1.2	10
41	De Novo Human Leukocyte Antigen Allosensitization in Heartmate 3 Versus Heartmate II Left Ventricular Assist Device Recipients. ASAIO Journal, 2022, 68, 226-232.	0.9	9
42	Transcriptomic heterogeneity of antibody mediated rejection after heart transplant with or without donor specific antibodies. Journal of Heart and Lung Transplantation, 2021, 40, 1472-1480.	0.3	9
43	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.3	9
44	Successful Percutaneous Transperineal Drainage of a Large Prostatic Abscess. Urology, 2010, 76, 1369-1370.	0.5	8
45	Outflow Graft Narrowing of the HeartMate 3 Left Ventricular Assist Device. Annals of Thoracic Surgery, 2023, 115, 1282-1288.	0.7	7
46	Predictors of Survival and Ventricular Recovery Following Acute Myocardial Infarction Requiring Extracorporeal Membrane Oxygenation Therapy. ASAIO Journal, 2022, 68, 800-807.	0.9	6
47	Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008968.	1.6	4
48	Continuousâ€flow mechanical circulatory support is not associated with early graft failure: An analysis of the International Society for Heart and Lung Transplantation registry. Clinical Transplantation, 2019, 33, e13752.	0.8	3
49	Impact of socioeconomic deprivation on evaluation for heart transplantation at an urban academic medical center. Clinical Transplantation, 2022, 36, e14652.	0.8	3
50	A Rare Case of Disseminated Tuberculosis and Hematological Malignancy in a Heart Transplant Recipient. Transplantation Proceedings, 2021, 53, 2626-2629.	0.3	2
51	Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donorâ€specific antibody levels. Clinical Transplantation, 2021, , e14524.	0.8	1
52	Letter by Clerkin et al Regarding Article, "Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation― Circulation, 2018, 137, 1870-1871.	1.6	0
53	How can we better inform our patients about postâ€heart transplantation survival? A conditional survival analysis. Clinical Transplantation, 2021, 35, e14449.	0.8	0
54	Local competition influences donor heart acceptance practice. Journal of Heart and Lung Transplantation, 2020, 39, 835-838.	0.3	0